TY - JOUR
T1 - Pathogenesis of comorbid epilepsy in Alzheimer’s disease and use of perampanel, an AMPA receptor inhibitor
AU - Kuzuya, Akira
AU - Ohara, Tomoyuki
AU - Akamatsu, Naoki
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Introduction: Alzheimer’s disease (AD) and epilepsy frequently co-occur and are risk factors for each other’s onset. In patients with AD-comorbid epilepsy, seizure control with appropriate anti-seizure medications (ASMs) is crucial, yet no established treatment guidelines exist. Recent studies indicate that α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (AMPARs) are involved in the pathogenesis of both diseases. Perampanel, an AMPAR antagonist, has been approved as an ASM. Areas covered: This review explains the relationship between AD and epilepsy and discusses the involvement of AMPARs. Furthermore, it focuses on and presents opinions regarding the role of AMPAR inhibitors in the treatment of AD-comorbid epilepsy. The authors searched for clinical studies that were published and identifiable in PubMed and Scopus (Jan 2015–Dec 2024) including the terms ‘Alzheimer’s disease’ or ‘dementia’ with ‘epilepsy’ or ‘seizure’. Expert opinion: Considering the hypothesis that AD and epilepsy are linked, creating a cycle that progresses both diseases via AMPARs, AMPAR inhibition may have beneficial effects in treatment of epilepsy in AD. Although evidence is limited, studies of perampanel have demonstrated symptomatic improvement in patients with AD-comorbid epilepsy. Perampanel may be particularly useful for specific subgroups of patients with AD-comorbid epilepsy, such as those with myoclonus, sleep disturbances, or poor medication adherence.
AB - Introduction: Alzheimer’s disease (AD) and epilepsy frequently co-occur and are risk factors for each other’s onset. In patients with AD-comorbid epilepsy, seizure control with appropriate anti-seizure medications (ASMs) is crucial, yet no established treatment guidelines exist. Recent studies indicate that α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (AMPARs) are involved in the pathogenesis of both diseases. Perampanel, an AMPAR antagonist, has been approved as an ASM. Areas covered: This review explains the relationship between AD and epilepsy and discusses the involvement of AMPARs. Furthermore, it focuses on and presents opinions regarding the role of AMPAR inhibitors in the treatment of AD-comorbid epilepsy. The authors searched for clinical studies that were published and identifiable in PubMed and Scopus (Jan 2015–Dec 2024) including the terms ‘Alzheimer’s disease’ or ‘dementia’ with ‘epilepsy’ or ‘seizure’. Expert opinion: Considering the hypothesis that AD and epilepsy are linked, creating a cycle that progresses both diseases via AMPARs, AMPAR inhibition may have beneficial effects in treatment of epilepsy in AD. Although evidence is limited, studies of perampanel have demonstrated symptomatic improvement in patients with AD-comorbid epilepsy. Perampanel may be particularly useful for specific subgroups of patients with AD-comorbid epilepsy, such as those with myoclonus, sleep disturbances, or poor medication adherence.
KW - Alzheimer’s disease
KW - anti-seizure medication
KW - epilepsy
KW - older adult patients
KW - perampanel
KW - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
UR - https://www.scopus.com/pages/publications/105020580312
UR - https://www.scopus.com/pages/publications/105020580312#tab=citedBy
U2 - 10.1080/14737175.2025.2581758
DO - 10.1080/14737175.2025.2581758
M3 - Review article
C2 - 41151846
AN - SCOPUS:105020580312
SN - 1473-7175
VL - 25
SP - 1399
EP - 1409
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 12
ER -